

SUBJECT INDEX VOLUME 24

- A**
- ACTH, 337, 568
 - Addiction, 568
 - Adenosine A₁-receptor, 86
 - Age effects, 522
 - Aggression, 37, 370, 502
 - Alcohol-nonpreferring rats, 691
 - Alcohol-preferring rats, 691
 - Allostasis, 97
 - Alternative splicing, 253
 - AMPA receptors, 253
 - Amphetamine, 170, 663
 - Amygdala, 430, 624
 - Animal models, 330
 - Anorexia nervosa, 706
 - Anpirtoline, 391
 - Antidepressants, 21, 379, 511, 617
 - Antipsychotic drug, 278
 - Anxiety, 31, 161, 430
 - Apomorphine, 278, 663
 - Astrocytes, 86
 - Auditory evoked potential, 671
 - Autonomic nervous system, 1
 - Awake, 141
- B**
- Behavior, 1, 691
 - Behavioral sensitization, 170, 680
 - Bioethics, 595
 - Bipolar disorder, 183, 192, 624
 - Blood-brain barrier, 55
 - Brain, 291, 652
 - Bulimia nervosa, 706
- C**
- CA1 pyramidal neuron, 141
 - CaM kinase, 21
 - Candidate genes, 467
 - Caudate nucleus, 47
 - CB₁ receptor, 198
 - CB₂ receptor, 198
 - CCK, 663
 - CCK-A, 663
 - Cholecystokinin, 161, 663
 - Citalopram, 240
 - Clomipramine, 511
 - Clozapine, 47, 55, 478
 - Cocaine, 170, 291, 300, 441, 568, 576
 - Cocaine abuse, 671
 - Cognition, 230
 - Competency, 595
 - Conditioned place aversion, 152
 - Conditioned reinforcer, 66
 - Conditioning, 680
 - Conflict, 430
 - Context, 680
 - Corticosterone, 531
 - Corticotrophin-releasing hormone (CRH), 531
 - Corticotropin-releasing factor (CRF), 1, 624
- D**
- Decision making, 595
 - Delta-9-tetrahydrocannabinol, 198
 - Dentate gyrus, 608
 - Depression, 21, 130, 337, 478, 531, 608, 617
 - Depression model, 632
 - Depressive disorder, 350
 - Desipramine, 379, 608
 - d*-Fenfluramine, 492
 - 5,7-Dihydroxytryptamine, 399
 - Dipeptidyl peptidase IV, 130
 - Diphosphoinositol polyphosphates, 640
 - Discrimination learning, 66
 - Dizocilpine, 663
 - Docosahexaenoic acid, 55
 - Dopamine, 55, 319, 561
 - Dopamine D₃ receptor, 170
 - Dopamine neurons, 410
 - Dopamine release, 410
 - Dopamine transporter, 561
 - Dopamine type 2 receptor, 553
 - Dopamine uptake transporter, 553
 - Dorsal raphe nucleus, 11
 - Drug addiction, 97
 - Drug development, 590
 - Duloxetine, 511
- E**
- Ecstasy, 230, 240
 - Electrocardiogram, 1
 - Electrophysiology, 691
 - Emesis, 198
 - Emotionality, 337
 - Endogenous serotonin (5-HT), 141
 - ERK, 267
 - Erythrocyte, 192
 - Estrus cycle, 502
 - Ethanol consumption, 430
 - Evoked potential, 230
 - Extended amygdala, 152
 - Extinction, 66
 - Extracellular signal-regulated kinase, 561
- F**
- Fatty acids, 55
 - Fever, 531
 - Firing activity, 141
 - Fluoxetine, 75, 370, 379, 502
 - Fluoxetine (Prozac), 531
 - Forced swim test, 391, 632
 - Forced swimming, 379
 - Fos, 152
 - Frontal brain, 337
 - Frontal cortex, 11, 183
- G**
- GABA, 706
 - Galanin, 706
 - Gene expression, 640
 - Genetics, 291
 - Genotype, 553
 - Glutamate, 545
 - Glycine, 330
- H**
- Habituation, 680
 - Haloperidol, 170, 240, 663
 - Heroin, 561
 - Hippocampus, 183, 330
 - HPA axis, 568
 - HPA system, 337
 - 5-HT depletion, 492
 - 5-HT transporter, 652
 - 5-HT_{1A} receptors, 11, 141, 209, 391, 522, 652
 - 5-HT_{1B} receptors, 391
 - 5-HT_{2A} receptors, 319, 652
 - 5-HT_{2C} receptors, 319, 478
 - 5-HTP, 75
 - Human, 553
 - 6-Hydroxydopamine, 680
 - 5-Hydroxyindoleacetic acid (5-HIAA), 370
 - 5-Hydroxytryptamine uptake, 11
 - Hypomania, 359
- I**
- Ibotenic acid, 330
 - Idazoxan, 379
 - Imipramine, 531
 - Immobilization stress, 420
 - Immunocytochemistry, 152
 - Immunotherapy, 130
 - Impulsivity, 370
 - In situ* hybridization, 170, 253, 545
 - Inbred mice, 291
 - Interactions, 379
 - Interferon, 130
 - Interleukin-1 (IL-1), 531
 - Interleukin-2, 130
 - Interleukin-6, 86
 - Intravenous and intracranial self-administration, 300
 - Ionotropic glutamate receptors, 545
 - Irritability, 502
 - Isamoltane, 391
- J**
- JNK, 267
- K**
- Kainic acid, 291
 - Kappa-opioids, 441

Ketamine, 590
Knock out mice, 576

L

Learning, 680
LETO, 663
Linoleic acid, 55
Lipopolysaccharide (LPS), 531
Lithium, 183, 192, 359, 640
Locomotion, 430
Locomotor activity, 319, 663
LSD, 478

M

Magnetic resonance spectroscopy, 359
Mania, 359
Marijuana, 198
m-Chlorophenylpiperazine, 492
MDMA, 230, 240
Medial frontal cortex, 66
Melatonin, 617
Memantine, 590
Memoriam, 710
Memory, 230
Meta-chlorophenylpiperazine, 31, 37
Methadone, 568
Methamphetamine, 330
3,4-Methylenedioxy-N-methylamphetamine, 240
Metyrapone, 568
Mianserin, 608
Mice, 300
Microdialysis, 11
Milnacipran, 379
Monkey, 230
Mood disorders, 209
Mood stabilizer, 624
Morphine, 75, 576
Mouse, 391
MRI, 47
mRNA differential display, 640
Myristic acid, 55

N

Neurochemistry, 691
Neurokinin A, 183
Neuroprotection, 86
Neuro-receptors, 467
Neurotensin, 170
Neurotoxicity, 492
Nicotine, 350, 576, 671
Nicotinic receptors, 671
Nitric oxide, 420
NMDA, 66, 590
Noradrenaline, 379
Norepinephrine, 617
Novelty, 680
Nucleus accumbens, 253, 410, 576
Nudix hydrolase, 640

O

Obsessive-compulsive disorder, 31
8-OH-DPAT, 379, 399
Oleic acid, 55
OLETF, 663
Open field test, 632
Opiate, 152, 561
Organotypic brain slices, 86
Oxidative stress, 420

P

p38 MAP kinase, 267
Palmitic acid, 55
Panic disorder, 161
Paraphilias, 37
Patient compliance, 192
p-Chlorophenylalanine, 399
Pedophilia, 37
Pentagastrin, 161
Perinatal alcohol, 691
Phencyclidine, 267
Pindolol, 209
Pineal gland, 617
Place conditioning, 75
Place preference, 576
Platelets, 511
Positron emission tomography, 209, 522
Pre-adolescents, 359
Prefrontal cortex, 253, 410, 545
Premenstrual dysphoria, 502
Prepulse inhibition, 399, 663
Primate, 370
Prolactin, 590
Protein phosphorylation, 21
Psychiatric disorders, 595
Psychosis, 671
Psychostimulant drugs, 680
Psychotherapy, 192

R

Randomized clinical trial, 350
Rat, 502, 680
Rat cerebellum, 267
Receptor autoradiography, 545
Recovery, 706
Reinforcement, 300
Resident intruder paradigm, 502
Response inhibition, 66
Reuptake inhibition, 511
Reversal learning, 66
Reward, 66, 300
Reward dysregulation, 97
RNA editing, 478
Rotational behavior, 680
rTMS, 337

S

Schizophrenia, 47, 253, 278, 330, 478, 595, 663

Seizures, 291
Selective serotonin reuptake inhibitors (SSRI), 11
Self-administration, 441
Sensitization, 441
Serotonin (5-HT) release, 492
Serotonin, 31, 37, 75, 240, 319, 370, 379, 399, 430, 467, 478, 502, 561
Serotonin reuptake inhibitor, 502
Signal transduction, 267
Single Photon Emission Tomography, 553
Smoking cessation, 350
SR 141716A, 198
SR 144528, 198
SSRI, 209
Startle, 663
Startle reflex, 399
Strains, 632
Stress, 300, 410, 680
Stress coping, 337
Striatum, 183, 545, 553
Substance P, 183
Suicide, 467, 478
Suicide attempt, 467
Synaptic plasticity, 21
Synaptic vesicle, 21

T

T₃, 632
TMS, 608
Tonic inhibition, 141
Trait anxiety, 300
Treatment outcome, 192
Tricyclic antidepressant, 652
Triiodothyronine, 652
Tumor Necrosis Factor- α (TNF α), 531
Tyramine, 511

U

U69593, 441
Unrestrained, 141

V

Valproic acid, 624
Vasopressin, 161
Ventral tegmental area, 410
Vesicular monoamine transporter, 561
Violence, 37

W

[¹¹C]WAY-100635, 209, 522
WIN 55, 212-2, 198
Withdrawal, 75, 152
Withdrawal symptoms, 350
Working memory, 66